Large two-biobank association resource
The study meta-analyses 11 prescription-derived phenotypes across UK Biobank and FinnGen, with overall sample sizes reaching 692,039 participants.
↳ Results, Discovery of 140 Genetic Associations; Table 1
Pain-related conditions are the leading cause of disability worldwide. Existing GWAS for chronic pain have mainly focused on individual pain-related disorders, which may not optimally capture the phenotype. Here, we define chronic pain based on prescription analgesic use ( ≥ 90 days) in two large biobanks (UK Biobank and FinnGen). GWAS meta-analyses of 11 prescription-based pain phenotypes identify 140 associations with chronic pain, including 78 novel (e.g. ARPP21, CNTNAP2) and 62 previously reported (e.g. SLC39A8, DCC, TRPM8) associations. Integrating these genetic associations with functional data including transcriptome-wide association studies, cell-type and pathway enrichment, and gene enrichment in mouse phenotypes identifies potential mechanisms involved in chronic pain, implicating oligodendrocyte differentiation, neuronal guidance, endolysosomal function and post-synaptic endosome recycling. Our study showcases how the use of prescription data to identify and characterize pain can provide insights into pain genetics and its underlying biology.
Integrating these genetic associations with functional data identifies potential mechanisms involved in chronic pain, implicating oligodendrocyte differentiation, neuronal guidance, endolysosomal function and post-synaptic endosome recycling.
functional enrichments are indirect and inherit uncertainty from the prescription-based phenotype
We detected many associations at loci previously reported in the literature, demonstrating that our prescription-based definitions of chronic pain are capturing relevant disease information.
known-locus overlap cannot separate pain signal from medication-use and opioid-related determinants
The strongest genetic correlations were found between pain duration phenotypes and depression or post-traumatic stress disorder.
reported LDSC estimates pass the stated multiple-testing threshold, subject to proxy-phenotype interpretation
Derived from the full evaluation — not a separate score.
Strengths
The study meta-analyses 11 prescription-derived phenotypes across UK Biobank and FinnGen, with overall sample sizes reaching 692,039 participants.
↳ Results, Discovery of 140 Genetic Associations; Table 1
Common-variant GWAS is supplemented by rare-variant burden tests, colocalisation, TWAS, cell-type analysis, mouse-phenotype enrichment, and genetic-correlation analyses.
↳ Methods, Overview of Analyses; Figure 6
The Discussion identifies restrictions arising from European ancestry, UK and Finnish healthcare systems, prescription ascertainment, and use of a UK Biobank LD reference for Finnish data.
↳ Discussion, limitations paragraphs
Limitations
The phenotype assumes 30-day prescriptions and combines diverse analgesics, while prolonged prescribing can reflect factors other than chronic pain. No direct comparison with diagnosis-based or patient-reported pain in the same cohorts is presented.
↳ Methods, Phenotype Definitions; Discussion, limitations paragraph
The Abstract reports 78 novel and 62 previously reported associations, but Table 1 sums to approximately 85 novel and 55 previously reported signals. The total of 140 also aggregates results across 11 overlapping phenotypes rather than representing 140 unique loci.
↳ Abstract; Table 1; Discussion, paragraph 1
Sex specificity is inferred from significant-versus-nonsignificant findings without a reported heterogeneity test, and functional enrichments remain hypothesis-generating rather than validated mechanisms.
↳ Results, Sex-Stratified Analysis and Functional Analysis; Discussion, paragraph 3
The study’s scale, two-biobank design, and extensive downstream analyses support a meaningful contribution to association mapping for analgesic-use phenotypes. Methodological Rigour is limited by the assumption that extended prescriptions directly identify chronic pain and by the absence of sensitivity analyses separating pain from prescribing behaviour, opioid response, or dependence. The Abstract’s novel/known split is not reproduced by Table 1, and the 140-signal total is not equivalent to a count of unique loci. The Discussion addresses several population and ascertainment limitations, but mechanistic and sex-specific interpretations remain stronger than the reported analyses warrant.
Nabu’s assessment, alongside the field’s view.
Are you an author of this paper?
The study meaningfully extends prescription-derived pain genetics through a large two-biobank meta-analysis and several downstream analyses. Its contribution is moderated by overlapping phenotype counts, an inconsistent novel/known split, and limited functional validation.
These combined meta-analyses identified 140 genome-wide associations
The GWAS, meta-analysis, rare-variant, colocalisation, TWAS, and enrichment procedures are extensively described using established tools. The central phenotype remains an unvalidated treatment-use proxy, and the headline signal count aggregates overlapping phenotypes without conditional analysis.
We assumed that each analgesic prescription is for 30 days duration.
The article follows a coherent sequence from phenotype construction through association discovery and functional interpretation. Precision is reduced by numerical discrepancies and by sex-specific and mechanistic interpretations that exceed the reported tests.
male pain perception may be more genetically driven than female pain perception
The paper engages prior pain GWAS and discusses ancestry, healthcare-system, LDSC, and ascertainment limitations. It does not fully propagate the multifactorial nature of analgesic prescribing into every claim about chronic-pain genes and mechanisms.
prescription drug use can be influenced by many factors
Caveats4 of 4 checks
The candidate-gene enumeration contains nine names despite stating seven, and the genetic-correlation reporting gives conflicting Bonferroni test counts. Neither issue establishes a changed association result.
Conflict of interest: not stated · Ethics approval: declared · Data availability: declared · Code availability: declared
93 of 93 checkable references verified
97 references in manuscript 4 have no canonical index record — counted, but not index-checkable 5 references confirmed by manual review
References not verified automatically are resolved manually within 24 hours.
No retraction or expression of concern found in Crossref (includes Retraction Watch).
Sources: Crossref (incl. Retraction Watch) ✓
The findings are observational genetic associations and computational enrichment analyses in population biobanks, with no experimental or interventional demonstration of any mechanism working.
“the evaluation of safer therapeutic opportunities in axonal guidance molecules deserves further exploration”
The paper names possible real-world uses of its findings, such as therapeutic targets for chronic pain, but does not specify who would act on them or in what setting.
Pharmaceutical and target-discovery researchers would take the prioritised genes and pathways, such as SEMA3F and axonal guidance, forward as candidate targets for new analgesic therapies.
The genetic associations and implicated mechanisms require functional validation in cellular and animal models before any therapeutic target can be confidently pursued.
Evaluated 13 Nov 2026 · GBD 2023 · glm_v1_3_3 · impact_profile_v1_3_3
AI-generated, human-governed. Something look off? Contact us to request a review.
Keep reading
Other papers Nabu has evaluated blind, starting with the same field.
Skelton, Mitchell, Assary, et al. · 2026 · Clinical medicine
We identified 80 independent genome-wide significant variants within 74 loci, 39 of which were newly associated with anxiety.
Well-supportedRossi, Sportelli, Kikidis, et al. · 2026 · Clinical medicine
Applying this framework to Psychiatric Genomics Consortium wave 3 genotypes identified 766 genes associated with schizophrenia
TentativeHuang, Meena, Achtari, et al. · 2026 · Clinical medicine
We prioritized 10 proteins potentially causally associated with both the arteriosclerotic/atherosclerotic markers and cardiovascular events.
Supported